An Emerging Global Leader in the New Generation of Antibiotic Therapies
Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of antibiotics.
Our lead patented candidate, RECCE® 327, continued to demonstrate broad spectrum antibiotic capabilities and was created to help address the urgent global health problem of antibiotic resistant superbugs.
Our initial focus is sepsis (blood poisoning) derived from Gram-positive, Gram-negative or superbug bacteria as well as H.pylori (Gastritis) and E. coli (Intestinal).
In 2017 RECCE® 327, was awarded Qualified Infectious Disease Product (QIDP) designation under the Generating Antibiotic Initiatives Now (GAIN) Act - labelling RECCE® 327 for Fast Track designation, plus 10 years of market exclusivity post approval.
Dr Graham Melrose, inventor of RECCE® antibiotics, discovered RECCE® 327 (327 being experimental book 3 – page 27) while experimenting in his retirement in a small laboratory of his Perth (Western Australia) home.
Following the discovery, Dr Melrose brought his experimentation to the attention of close family members James Graham (Executive Director - Marketing & Business Development) and Michele Dilizia (Executive Director - Regulatory & Microbiology) who assisted in getting Dr Melrose into a proper laboratory facility at Bentley’s Technology Park to expand upon the promising research.
In the early days, James would support in the capital raising initiates, while Michele as a qualified medical scientist was active in laboratory practices.
Recce (pronounced Re-Key) originates from the military term ‘Reconnaissance’ as a military tactic – ‘the aggressive assessment of the disposition of the enemy’. In other words, get troops behind enemy lines, identify the enemy, eliminate the threat and escape without being noticed.
We have transitioned that philosophy to anti-infectives, where our antibiotic is designed to:
- Enter the human body,
- Bear down on the threat (deadly bacteria),
- Eliminate that threat
- Get out without being noticed (side effects)
Our Vision & Values
“To target the global health problem of superbugs”
New synthetic (polymer based) drugs are uniquely used for targeting major human health threats. With over 30 years of polymer experience, Dr Melrose and team are well placed to broaden Recce’s technical capabilities.
Patents are the value of any technology company and Recce Pharmaceuticals Ltd is no exception. With a track record of applying for a patent and it always being accepted, Recce is well positioned to continue expanding its wholly owned international patent portfolio.
As an Australian Stock Exchange (ASX:RCE) listed company, Recce Pharmaceuticals Ltd is funded to pursue its drug development activities, starting with the world’s largest pharmaceutical market the USA – as regulated by the with the U.S. Food and Drug Administration. Recce’s capitalistic culture sees all technical endeavours focused around a commercial outcome.